Clearmind Shares Leap After Japanese Patent Application Publication for MEAI Depression Therapy
Clearmind Medicine Inc reported the publication of a Japanese patent application covering proprietary compositions that include 5-Methoxy-2-aminoindan (MEAI), a non-hallucinogenic candidate for treating depression. The announcement preceded a 95% jump in the company's shares in premarket trading, and the filing expands a global intellectual propert…